Oncotelic Therapeutics Inc. (OTCQB: OTLC) Advances Drug Delivery Against BBB Challenge
Expert Analysis Oncotelic Therapeutics Inc. (OTCQB: OTLC) is making significant strides in tackling the persistent challenge of delivering drugs across the blood-brain barrier (BBB). As many neurological conditions remain difficult to treat due to the protective nature of the BBB, developing innovative delivery platforms is crucial. OTLC’s novel approach positions the company as a potential leader in overcoming this long-standing obstacle in drug development. The implications of successfully crossing the…









